Down almost 45% year-to-date, Novo Nordisk (NVO) has attracted a few finpub articles claiming a mispricing or severe undervaluation. However, the question that everyone should start screaming at the top of their lungs is: BASED ON WHAT!? Often, the answer comes down to the author’s assumption of earnings trajectory, cash flows and weighted average cost of capital.To be quite blunt, not utilizing KDE to trade — especially options trading — is tantamount to malpractice. You’re already at a disadvantage on Wal ...